Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biomarkers for mesothelioma.

Arnaud Scherpereel1, Y C Gary Lee

  • 1Pulmonary and Thoracic Oncology Department, Hopital Calmette, Lille, France.

Current Opinion in Pulmonary Medicine
|May 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outperformed by enzymes: why saline lavage falls short of intrapleural enzyme therapy in pleural infection.

The European respiratory journal·2026
Same author

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Accelerometry daily steps count is associated with overall survival in malignant pleural effusion patients.

Respiratory medicine·2026
Same author

The Third Pleural Effusion and Symptom Evaluation (PLEASE-3) Study: <i>Bendopnoea in patients with pleural effusion</i>.

The European respiratory journal·2026
Same author

Development and Evaluation of the Early Pleurodesis via IPC for Treatment of Malignant Effusion Protocol.

Respiration; international review of thoracic diseases·2026
Same author

Pleural Infection as the First Presentation of a Large Retroperitoneal Abscess.

Respirology case reports·2026

Biomarkers like soluble mesothelin-related peptide (SMRP) show promise for mesothelioma diagnosis and monitoring. However, current markers lack the accuracy to replace traditional methods, requiring further research for clinical application.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Cancer Diagnostics

Background:

  • Mesothelioma is an aggressive, incurable cancer with increasing global incidence.
  • Accurate diagnosis, prognosis, and monitoring are crucial for mesothelioma patient management.
  • Novel biomarkers are actively being investigated to improve mesothelioma care.

Purpose of the Study:

  • To review recent findings on candidate biomarkers for mesothelioma.
  • To evaluate the diagnostic and prognostic utility of novel mesothelioma markers.
  • To assess the potential of biomarkers in disease monitoring and risk prediction.

Main Methods:

  • Analysis of global gene profiling studies.
  • Evaluation of soluble mesothelin-related peptide (SMRP), osteopontin, and megakaryocyte potentiating factor.

Related Experiment Videos

  • Assessment of marker performance in serum and pleural fluid.

    • Main Results:

    • No single gene profiling marker reliably identifies all mesothelioma subtypes or differentiates from other cancers.
    • Soluble mesothelin-related peptide (SMRP) shows reasonable diagnostic accuracy in serum/pleural fluid but has limitations (e.g., sarcomatoid mesothelioma, false positives in other cancers).
    • Osteopontin lacks diagnostic specificity but may aid in disease monitoring; SMRP's role in monitoring and risk prediction warrants further investigation.

    Conclusions:

    • Current candidate biomarkers are insufficient to replace cytohistology for mesothelioma diagnosis.
    • Elevated SMRP suggests mesothelioma but negative results do not exclude the disease.
    • Further research is needed to establish the role of SMRP in disease monitoring and predicting mesothelioma development in at-risk populations.